^
Association details:
Biomarker:BRAF rearrangement
Cancer:Melanoma
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma

Published date:
07/07/2023
Excerpt:
The purpose of the current retrospective analysis was to evaluate whether the mutational signature of metastatic melanoma had an impact on ICI treatment outcomes such as progression-free and overall survival....The percentage of patients who achieved CR as the BORR after initial ICI treatment was 45.5% for the BRAF V600 mutation subset, 38.5% for NRAS mutant patients, 37.5% for NF1 mutant patients, and 55.6% for triple negative patients (p > 0.05 via chi-square test). No patients with a BRAF fusion or gene rearrangement responded to ICI or 2nd line PD-1 antibody plus targeted therapy treatment (BORR of 0%)....
DOI:
https://doi.org/10.3390/cancers15133527